Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04978428 · ClinicalTrials.gov registry record · Phase 2
Epidiolex in Obsessive Compulsive Disorder and Related Disorders
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04978428 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 4 participants.
The verdict
NCT04978428, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.
Interventions
- DRUG Cannabidiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2025-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04978428
The ClinicalTrials.gov registry entry for NCT04978428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cannabidiol is the first listed.
NCT04978428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04978428 about?
NCT04978428 is a clinical study titled "Epidiolex in Obsessive Compulsive Disorder and Related Disorders". The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.
What is the current status of trial NCT04978428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2022-04-14. Estimated completion is 2025-11-01.
What interventions are being tested in trial NCT04978428?
The interventions under investigation include: Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT04978428?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.